Ignite Creation Date:
2024-05-05 @ 7:32 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00698906
Status:
COMPLETED
Last Update Posted:
2008-06-17
First Post:
2008-06-13
Brief Title:
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix-B in Adults Aged 19-40 y
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bios HBV-MPL Vaccine Injected as a 0 6 Months Schedule With That of Engerix-B Injected as a 0 1 6 Months Schedule in Healthy Adults Aged 19-40 Years
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the immunogenicity and safety of different formulations of the HBV-MPL vaccine administered according to a 2-dose schedule and compare it to that of Engerix-B administered according to a 3-dose schedule in order to determine the optimal dose of each component of the candidate HBV-MPL vaccine when administered at 0 and 6 months
Detailed Description:
At the time of conduct of this study the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None